Huntington’s Disease Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Sangamo Therapeutics, Spark therapeutics, Chong Kun Dang Pharma

The Huntington’s Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Huntington’s Disease Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Huntington’s Disease Market.

Some of the key takeaways from the Huntington’s Disease Pipeline Report:

• Companies across the globe are diligently working toward developing novel Huntington’s Disease treatment therapies with a considerable amount of success over the years. 
• Huntington’s Disease companies working in the treatment market are Sangamo Therapeutics, Spark therapeutics, Chong Kun Dang Pharmaceutical, Neuvivo, UniQure Biopharma, Wave Life Sciences, Novartis, Sage Therapeutics, Annexon, Neurocrine Biosciences, Prilenia Therapeutics, and others, are developing therapies for the Huntington’s Disease treatment 

• Emerging Huntington’s Disease therapies in the different phases of clinical trials are- TAK-686, Huntington’s Disease therapy, CKD-504, NP 001, rAAV5-miHTT, WVE003, Branaplam, SAGE-718, ANX005, Valbenazine, Pridopidine, and others are expected to have a significant impact on the Huntington’s Disease market in the coming years.   
• In August 2022, In order to undertake a Phase I/II trial for its innovative Huntington’s Disease (HD) gene treatment, BV-101, through its subsidiary BrainVectis in France, Asklepios BioPharmaceutical, a fully owned and independently run subsidiary of Bayer AG, got approval. The National Agency for Safety of Medicines and Health Products (ANSM), the nation’s regulatory drug agency, has granted the corporation permission to start seeking volunteers after the relevant Ethics Committee approved the trial protocol.
• In March 2022, The PIVOT-HD Phase II clinical trial investigating PTC518 in patients with Huntington’s disease (HD) has begun, according to PTC Therapeutics. An international trial called PIVOT-HD is beginning in the US. PTC518 is a small chemical splicing modifier that may be taken orally and was created specifically to reduce huntingtin mRNA and protein. The underlying cause of HD is not currently being treated.
• In January 2022, A new Phase II trial to assess tominersen in Huntington’s disease (HD) has been planned, according to an announcement by Ionis Pharmaceuticals and its partner Roche. Tominersen may benefit younger adult patients with reduced disease load, according to exploratory posthoc analysis conducted after treatment in the Phase III GENERATION HD1 study was stopped. It is necessary to confirm these findings in a randomised, placebo-controlled trial.

Huntington’s Disease Overview

Huntington’s disease is a genetically transmitted, neurodegenerative ailment that gradually impairs cognitive function and memory (dementia) as well as the development of uncontrollable motions of the hands, feet, face, and body.

Get a Free Sample PDF Report to know more about Huntington’s Disease Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/report-store/huntingtons-disease-pipeline-insight

Emerging Huntington’s Disease Drugs Under Different Phases of Clinical Development Include:

• TAK-686: Sangamo Therapeutics
• Huntington’s Disease therapy: Spark therapeutics
• CKD-504: Chong Kun Dang Pharmaceutical
• NP 001: Neuvivo
• rAAV5-miHTT: UniQure Biopharma
• WVE003: Wave Life Sciences
• Branaplam: Novartis
• SAGE-718: Sage Therapeutics
• ANX005: Annexon
• Valbenazine: Neurocrine Biosciences
• Pridopidine: Prilenia Therapeutics

Huntington’s Disease Route of Administration

Huntington’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Huntington’s Disease Molecule Type

Huntington’s Disease Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Huntington’s Disease Pipeline Therapeutics Assessment

• Huntington’s Disease Assessment by Product Type
• Huntington’s Disease By Stage and Product Type
• Huntington’s Disease Assessment by Route of Administration
• Huntington’s Disease By Stage and Route of Administration
• Huntington’s Disease Assessment by Molecule Type
• Huntington’s Disease by Stage and Molecule Type

DelveInsight’s Huntington’s Disease Report covers around 50+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Huntington’s Disease product details are provided in the report. Download the Huntington’s Disease pipeline report to learn more about the emerging Huntington’s Disease therapies

Some of the key companies in the Huntington’s Disease Therapeutics Market include:

Key companies developing therapies for Huntington’s Disease are – Prilenia Therapeutics, Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, SAGE Therapeutics, PTC Therapeutics, WaVe life Sciences, Novartis, Neurimmune Therapeutics, SOLA Biosciences, UniQure Biopharma, Roche, Annexon, Inc., Azevan Pharmaceuticals, SOM Innovation Biotech SA, Asklepios BioPharmaceutical, Luye Pharma Group Ltd., BrainStorm Cell Therapeutics, Voyager Therapeutics, Passage Bio, Locana Bio, Ceptur Therapeutics, Enzerna Biosciences, AFFiRiS AG, Arvinas, Atalanta Therapeutics, Anima Biotech, and others.

Huntington’s Disease Pipeline Analysis:

The Huntington’s Disease pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Huntington’s Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Huntington’s Disease Treatment.
• Huntington’s Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Huntington’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Huntington’s Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Huntington’s Disease drugs and therapies

Huntington’s Disease Pipeline Market Drivers

• Introduction of disease-modifying drugs, further understanding in pathogenesis are some of the important factors that are fueling the Huntington’s Disease Market.

Huntington’s Disease Pipeline Market Barriers

• However, lesser approved therapies, stringent regulations and other factors are creating obstacles in the Huntington’s Disease Market growth.

Scope of Huntington’s Disease Pipeline Drug Insight    

• Coverage: Global
• Key Huntington’s Disease Companies: Sangamo Therapeutics, Spark therapeutics, Chong Kun Dang Pharmaceutical, Neuvivo, UniQure Biopharma, Wave Life Sciences, Novartis, Sage Therapeutics, Annexon, Neurocrine Biosciences, Prilenia Therapeutics, and others
• Key Huntington’s Disease Therapies: TAK-686, Huntington’s Disease therapy, CKD-504, NP 001, rAAV5-miHTT, WVE003, Branaplam, SAGE-718, ANX005, Valbenazine, Pridopidine, and others
• Huntington’s Disease Therapeutic Assessment: Huntington’s Disease current marketed and Huntington’s Disease emerging therapies
• Huntington’s Disease Market Dynamics: Huntington’s Disease market drivers and Huntington’s Disease market barriers 

Request for Sample PDF Report for Huntington’s Disease Pipeline Assessment and clinical trials

Table of Contents 

1. Huntington’s Disease Report Introduction

2. Huntington’s Disease Executive Summary

3. Huntington’s Disease Overview

4. Huntington’s Disease- Analytical Perspective In-depth Commercial Assessment

5. Huntington’s Disease Pipeline Therapeutics

6. Huntington’s Disease Late Stage Products (Phase II/III)

7. Huntington’s Disease Mid Stage Products (Phase II)

8. Huntington’s Disease Early Stage Products (Phase I)

9. Huntington’s Disease Preclinical Stage Products

10. Huntington’s Disease Therapeutics Assessment

11. Huntington’s Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Huntington’s Disease Key Companies

14. Huntington’s Disease Key Products

15. Huntington’s Disease Unmet Needs

16 . Huntington’s Disease Market Drivers and Barriers

17. Huntington’s Disease Future Perspectives and Conclusion

18. Huntington’s Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services